ERBB2 and breast cancer: BC is considered HER2-positive when immunohistochemistry (IHC) assay reveals HER2 overexpression (score 3+) or there is ERBB2 amplification on an in-situ hybridization (ISH) assay, which usually is performed if IHC shows a score of 2 +.